vTv Therapeutics Inc
$ 38.12
3.73%
17 Apr - close price
- Market Cap 150,141,000 USD
- Current Price $ 38.12
- High / Low $ 38.12 / 36.01
- Stock P/E N/A
- Book Value 5.19
- EPS -3.20
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.79 %
- 52 Week High 44.00
- 52 Week Low 14.00
About
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.
Analyst Target Price
$53.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-06 | 2025-08-12 | 2025-05-07 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-09 | 2023-08-11 | 2023-05-11 |
| Reported EPS | -0.58 | -1.08 | -0.92 | -0.77 | -0.552 | -0.8766 | -0.8089 | -1.1747 | -1.67 | -3.2 | -0.07 | -0.06 |
| Estimated EPS | -1.088 | -1 | -1.12 | -0.815 | -0.87 | None | None | None | -0.07 | -0.08 | -0.07 | -0.09 |
| Surprise | 0.508 | -0.08 | 0.2 | 0.045 | 0.318 | 0 | 0 | 0 | -1.6 | -3.12 | 0 | 0.03 |
| Surprise Percentage | 46.6912% | -8% | 17.8571% | 5.5215% | 36.5517% | None% | None% | None% | -2285.7143% | -3900% | 0% | 33.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTVT
2026-04-16 21:38:54
Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G/A, disclosing their beneficial ownership in vTv Therapeutics (VTVT). Integrated Core Strategies (US) LLC holds a 5.0% stake, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each hold 5.7% of the Class A Common Stock. A Joint Filing Agreement dated April 15, 2026, formalizes this group reporting of shared voting and dispositive power.
2026-04-08 06:10:39
vTv Therapeutics announced giving 4,000 stock options to a non-executive employee as an inducement for employment, as per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $39.54, vest over four years, and have a 10-year term. The company is a late-stage biopharmaceutical firm focused on developing cadisegliatin for type 1 diabetes.
2026-04-07 22:09:33
vTv Therapeutics Inc. announced it has granted 4,000 stock options to a non-executive employee as an inducement to employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $39.54 per share, vesting over four years. This move highlights the company's efforts to attract and retain talent as it focuses on developing cadisegliatin, an oral treatment for type 1 diabetes.
2026-04-06 20:10:39
vTv Therapeutics (NASDAQ:VTVT) has shown significant stock growth of 168% in the last year, despite being an unprofitable company. The analysis indicates that the company has a cash runway of about 3.5 years based on its US$89m cash reserves and US$25m annual cash burn, suggesting it can fund its growth without immediate concerns. Furthermore, its cash burn of US$25m is a small percentage (4.9%) of its US$511m market capitalization, indicating that raising additional capital through shares or debt would be relatively easy if needed.
2026-03-27 20:40:23
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a 5.0% stake in vTv Therapeutics Inc. (VTVT) through a Schedule 13G filing. This passive investment accounts for 198,237 shares of Class A Common Stock, with shared voting and dispositive power. The filing, dated March 24, 2026, includes a Joint Filing Agreement and clarifies that while Millennium-related entities control and have investment discretion over these shares, it does not automatically constitute an admission of beneficial ownership.
2026-03-21 06:11:12
vTv Therapeutics Inc. announced its management will participate in the 38th Annual ROTH Conference, featuring a fireside chat and investor meetings on March 23, 2026. The company is a late-stage biopharmaceutical firm focused on developing cadisegliatin for type 1 diabetes. Cadisegliatin is an oral glucokinase activator currently in a US Phase 3 trial and has received Breakthrough Therapy designation from the FDA.
